Iovance Biotherapeutics' MDA-TIL Phase II trial was terminated due to lack of efficacy, significantly decreasing its Phase Transition Success Rate (PTSR) in ovarian, colorectal, and pancreatic cancers.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.